AML | Clinical

Venetoclax Improves Treatment Landscape for Older Patients With AML

January 11, 2021

Tapan M. Kadia, MD, discusses the treatment options for patients with newly diagnosed acute myeloid leukemia.

Younger Patients, Select Subsets in AML May Have Higher Chances of Long-Term Survival

January 09, 2021

Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.

FDA Lifts Partial Clinical Hold for Phase 2 Study of MT-401 in Post-Transplant AML

January 06, 2021

The FDA lifted the partial clinical hold that was placed on a phase 2 study of MT-401 as treatment of patients with post-transplant acute myeloid leukemia.

Phase 3 Study of Iomab-B With Bone Marrow Transplant in AML to Continue to Full Enrollment

January 05, 2021

An Independent Data Monitoring Committee has recommended the pivotal phase 3 SIERRA study continue as planned to full enrollment of 150 patients based on the findings from a pre-planned ad hoc interim analysis of the study.

Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome

January 02, 2021

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Sabatolimab Appears Promising for Combination Use With HMAs in AML, MDS

December 25, 2020

Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

LACEWING Update: Gilteritinib Plus Azacitidine Does Not Improve OS in Newly Diagnosed AML

December 21, 2020

A review by an Independent Data Monitoring Committee determined that combination of gilteritinib plus azacitidine would not likely improve overall survival compared with azacitidine alone in patients newly diagnosed FLT3-positive acute myeloid leukemia who were ineligible for intensive induction chemotherapy, missing the primary end point of the phase 3 LACEWING clinical trial.